Sandostatin Impairs Postresection Intestinal Adaptation in a Rat Model of Short Bowel Syndrome
Tóm tắt
Because of its antisecretory properties, sandostatin has been advocated for the treatment of patients with short bowel syndrome (SBS). This study was conducted to determine the effect of sandostatin on structural intestinal adaptation, cell proliferation and apoptosis in a rat model of SBS. Sprague-Dawley rats were divided into three experimental groups: Sham rats underwent bowel transection, SBS rats underwent 75% small bowel resection, and SBS-sandostatin rats underwent bowel resection and were treated with sandostatin (SBS-SND). Parameters of intestinal adaptation, enterocyte proliferation, and enterocyte apoptosis were determined on day 14 following operation. We have demonstrated that SBS-SND animals demonstrated lower (vs SBS rats) duodenal and jejunal bowel weights, jejunal and ileal mucosal weight, jejunal and ileal mucosal DNA and protein, jejunal and ileal villus height, cell proliferation index in the ileum, and enterocyte apoptosis in jejunum and ileum. We conclude that in a rat model of SBS sandostatin decreases cell proliferation and inhibits structural intestinal adaptation.
Tài liệu tham khảo
Booth IW, Lander AD: Short bowel syndrome. Bailliere's Clin Gastroenterol 12:739–772, 1998
Coran AG, Spivak D, Teitelbaum DH: An analysis of the morbidity and mortality of short bowel syndrome in the pediatric age group. Eur J Pediatr Surg 9:228–230, 1999
Schwartz MZ, Kuenzler KA: Pharmacotherapy and growth factors in the treatment of short bowel syndrome. Semin Pediatr Surg 10:81–90, 2001
Hodin RA, Salinger P, Meng S: Small bowel adaptation: counterregulatory effects of epidermal growth factor and somatostatin on the program of early gene expression. Surgery 118:206–211, 1995
Vanderhoof JA, Kollman KA: Lack of inhibitory effect of octreotide on intestinal adaptation in short bowel syndrome in the rat. J Pediatr Gastroenterol Nutr 26:241–244, 1997
Chomczynski P: A reagent for the single-step simultaneous isolation of RNA, DNA and proteins from cell and tissue samples. BioTechniques 15:532–536, 1993
Robinson MK, Ziegler TR, Wilmore DW: Overview of intestinal adaptation and its stimulation. Eur J Pediatr Surg 9:200–206, 1999
Hall PA, Coates PJ, Ansari B, Hopwood D: Regulation of cell number in the mammalian gastrointestinal tract: The importance of apoptosis. J Cell Sci 107:3569–3577, 1994
Lamers CBHW: Clinical and pathophysiological aspects of somatostatin and the gastrointestinal tract. Acta Endocrinol Suppl 286:19–25, 1987
Harris AG: Somatostatin and somatostatin analogues: pharmacokinetics and pharmacodynamic effects. Gut Suppl 3:S1–S4, 1994
Arnold R, Simon B, Wied M: Treatment of neuroendocrine GEP tumours with somatostatin analogues: a review. Digestion Suppl 62:184–191, 2000
Tomassetti P, Migliori M, Corinaldesi R, Gullo L: Treatment of gastroenteropancreatic neuroendocrine tumours with octreotide LAR. Aliment Pharmacol Ther 14:557–560, 2000
Arnold R, Frank M: Gastrointestinal endocrine tumours: medical management. Baillieres Clin Gastroenterol 10:737–759, 1996
Beaugerie L, Baumer P, Chaussade S, Berard H, Rozenbaum W, Pialoux G, Le-Quintrec Y, Schwartz JC, Lecomte JM: Treatment of refractory diarrhoea in AIDS with acetorphan and octreotide: a randomized crossover study. Eur J Gastroenterol Hepatol 8:485–489, 1996
Li-Ling J, Irving M: Somatostatin and octreotide in the prevention of postoperative pancreatic complications and the treatment of enterocutaneous pancreatic fistulas: a systematic review of randomized controlled trials. Br J Surg 88:190–199, 2001
Dorta G: Role of octreotide and somatostatin in the treatment of intestinal fistulae. Digestion 60(suppl):253–256, 1999
Greenberg R, Haddad R, Kashtan H, Kaplan O: The effects of somatostatin and octreotide on experimental and human acute pancreatitis. J Lab Clin Med 135:112–121, 2000
Moloney M, Wilkinson M: Early administration of somatostatin and efficacy of sclerotherapy in acute oesophageal variceal bleeds: the European Acute Bleeding Oesophageal Variceal Episodes (ABOVE) randomised trial. Gastrointest Endosc 51:372–374, 2000
Dharmsathaphorn K, Gorelick FS, Sherwin RS, Cataland S, Dobbins JW: Somatostatin decreases diarrhea in patients with the short bowel syndrome. J Clin Gastroenterol 4:521–524, 1982
Nightingale JM, Walker ER, Burnham WR, Farthing MJ, Lennard-Jones JE: Octreotide (a somatostatin analogue) improves the quality of life in some patients with a short intestine. Aliment Pharmacol Ther 3:367–373, 1989
Ladefoged K, Christensen KC, Hegnhoj J, Jarnum S: Effect of a long acting somatostatin analogue SMS 201–995 on jejunostomy effluents in patients with severe short bowel syndrome. Gut 30:943–949, 1989
Rodrigues CA, Lennard-Jones JE, Thompson DG, Farthing MJ: The effects of octreotide, soy polysaccharide, codeine and loperamide on nutrient, fluid and electrolyte absorption in the short-bowel syndrome. Aliment Pharmacol Ther 3:159–169, 1989
Stange EF, Schneider A, Schusdziarra V, Ditschuneit H: Inhibitory effects of somatostatin on growth and differentiation in cultured intestinal mucosa. Horm Metab Res 16:74–78, 1984
Schneider A, Grosch G, Stange EF, Ditschuneit H. Influence of triamcinolone and somatostatin on morphometric parameters of cultured intestinal mucosa. In Vitro Cell Dev Biol 22:647–652, 1986
Bass BL, Fischer BA, Richardson C, Harmon JW: Somatostatin analogue treatment inhibits post-resectional adaptation of the small bowel in rats. Am J Surg 161:107–111, 1991
Thompson JS, Nguyen BLT, Harty RF: Somatostatin analogue inhibits intestinal regeneration. Arch Surg 128:385–389, 1993
Sagor GR, Ghatei MA, O'shaughnessy DJ, Al-Mukhtar MYT, Wright NA, Bloom SR: Influence of somatostatin and bomebesin on plasma enteroglucagon and cell proliferation after intestinal resection in the rat. Gut 26:89–94, 1985
Thompson JS: Epidermal growth factor inhibits somatostatin-induced apoptosis. J Surg Res 81:95–100, 1999